期刊
CYTOMETRY PART B-CLINICAL CYTOMETRY
卷 100, 期 1, 页码 63-71出版社
WILEY
DOI: 10.1002/cyto.b.21970
关键词
drug development; flow cytometry; immunotherapeutics; receptor occupancy; validation
Flow cytometry is well-suited for monitoring drug-to-target engagement through receptor occupancy assays (ROA), but there are challenges in the design and implementation, especially in cases of receptor modulation or low target-antigen expression levels. Best practices for designing, optimizing, and validating ROA are proposed to address these challenges.
In the development of therapeutic compounds that bind cell surface molecules, it is critical to demonstrate the extent to which the drug engages its target. For cell-associated targets, flow cytometry is well-suited to monitor drug-to-target engagement through receptor occupancy assays (ROA). The technology allows for the identification of specific cell subsets within heterogeneous populations and the detection of nonabundant cellular antigens. There are numerous challenges in the design, development, and implementation of robust ROA. Among the most difficult challenges are situations where there is receptor modulation or when the target-antigen is expressed at low levels. When the therapeutic molecules are bi-specific and bind multiple targets, these challenges are increased. This manuscript discusses the challenges and proposes best practices for designing, optimizing, and validating ROA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据